4DX.ASX: Quarterly Activity Report and Appendix 4C

Quarterly Activity Report and Appendix 4C

Stock	4DMEDICAL Ltd (4DX.ASX)
Release Time	31 Jul 2025, 4:38 p.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

4DMedical Secures $10M Strategic Investment, Advances CT:VQ™ to FDA Clearance

Key Points

Operating revenue for FY25 up 56% vs FY24, with gross margins >90%
Underlying SaaS Revenue for FY25 up 95% vs FY24
4DMedical secures $10m strategic investment from Pro Medicus to accelerate CT:VQ™ and commercial pipeline

Full Summary

4DMedical Limited (ASX:4DX) announced its Quarterly Activity Report and Appendix 4C Cash Flow Report for the quarter ended 30 June 2025. The company reported strong financial performance, with operating revenue for FY25 up 56% versus FY24, and gross margins exceeding 90%. Underlying SaaS revenue for FY25 increased by 95% compared to FY24. 4DMedical also secured a $10 million strategic investment from leading global medical imaging software company Pro Medicus (ASX:PME). This investment will provide 4DMedical with growth capital to accelerate its commercial pipeline for existing products and advance its revolutionary CT:VQ™ technology towards regulatory clearance in the United States. The company also reported continued growth in global site and scan numbers, with 388 sites globally, up 7.5% quarter-on-quarter and 60% year-on-year. 4DMedical filed for FDA 510(k) submission for its CT:VQ™ product, a non-contrast CT-based lung imaging software tool for assessing both ventilation (V) and perfusion (Q) in the lungs. The company has also secured key reference site renewals and contract wins, including with the University of Michigan, Stanford University, and Intermountain Health. Additionally, 4DMedical's partner Olympus Corporation launched a full market release of its SeleCT™ Screening program, powered by 4DMedical's lung density analysis technology.

Guidance

4DMedical expects to receive its annual R&D tax receipt of $6.0 million in the coming weeks, providing additional funding to support its growth initiatives.

Outlook

4DMedical is well-positioned to capitalize on the anticipated FDA clearance of its CT:VQ™ technology, which is poised to disrupt the current market for ventilation perfusion imaging. The company's growing commercial momentum, including the strategic investment from Pro Medicus and the expanding partnerships, provide a strong foundation for future growth.